XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Balance Sheet Components (Tables)
 3 Months Ended
Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract]  
Schedule of Intangible Assets Intangible assets consisted of the following (in thousands of dollars):
 March 31, 2023December 31, 2022Weighted Average Remaining Amortization Period (Years)
 Gross Carrying AmountAccumulated AmortizationNet Carrying AmountGross Carrying AmountAccumulated AmortizationNet Carrying Amount
Percepta product technology$16,000 $(8,533)$7,467 $16,000 $(8,267)$7,733 7
Prosigna product technology4,120 (915)3,205 4,120 (847)3,273 11
Prosigna customer relationships2,430 (1,620)810 2,430 (1,499)931 1
nCounter Dx license46,880 (10,418)36,462 46,880 (9,636)37,244 11
LymphMark product technology990 (471)519 990 (436)554 4
Decipher product technology90,000 (18,484)71,516 90,000 (16,234)73,766 8
Decipher trade names4,000 (1,643)2,357 4,000 (1,443)2,557 3
HalioDx developed technology40,400 (7,001)33,399 39,724 (5,899)33,825 8
HalioDx customer relationships4,680 (1,369)3,311 4,602 (1,144)3,458 5
HalioDx customer backlog6,639 (2,759)3,880 6,528 (2,303)4,225 2
Total finite-lived intangibles216,139 (53,213)162,926 215,274 (47,708)167,566 8.4
In-process research and development7,300 — 7,300 7,300 — 7,300 
Total intangible assets$223,439 $(53,213)$170,226 $222,574 $(47,708)$174,866 
Schedule of Future Aggregate Amortization Expense The estimated future aggregate amortization expense as of March 31, 2023 is as follows (in thousands of dollars):
Year Ending December 31,Amounts
2023 remainder of year$16,037 
202421,343 
202520,215 
202618,359 
202717,752 
Thereafter69,220 
Total$162,926 
Schedule of Accrued Liabilities
Accrued liabilities consisted of the following (in thousands of dollars):
 
 March 31, 2023December 31, 2022
Accrued compensation expenses$21,953 $30,637 
Accrued other8,688 7,137 
Total accrued liabilities$30,641 $37,774